Stockscreener 앱 받기
13.84
0.80%
0.11
시간 외 거래:
13.84
전일 마감가:
$13.73
열려 있는:
$13.76
하루 거래량:
35.43M
Relative Volume:
7.32
시가총액:
$987.60M
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
-4.1939
EPS:
-3.3
순현금흐름:
$-167.04M
1주 성능:
+53.27%
1개월 성능:
+57.27%
6개월 성능:
+565.38%
1년 성능:
+515.11%
1일 변동 폭
$13.76
$13.85
1주일 범위
$7.08
$25.00
52주 변동 폭
$0.783
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
명칭
Ventyx Biosciences Inc
전화
(760) 407-6511
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
13.84 | 979.75M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-03-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-03-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-11-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Wells Fargo | Overweight |
| 2022-12-19 | 개시 | Goldman | Buy |
| 2022-11-17 | 개시 | Morgan Stanley | Overweight |
| 2022-09-07 | 개시 | Stifel | Buy |
| 2022-09-01 | 개시 | H.C. Wainwright | Buy |
| 2022-05-09 | 개시 | Credit Suisse | Outperform |
| 2022-03-31 | 개시 | Canaccord Genuity | Buy |
| 2022-02-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-15 | 개시 | Jefferies | Buy |
| 2021-11-15 | 개시 | Piper Sandler | Overweight |
모두보기
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Lilly To Buy Ventyx Biosciences For $1.2 Billion To Expand Oral Inflammation Pipeline - Pulse 2.0
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc.VTYX - PR Newswire
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - PR Newswire
Ventyx Biosciences to be Sold to Eli Lilly for $14 per Share - Intellectia AI
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly - Wilson Sonsini
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition By Investing.com - Investing.com Nigeria
Ventyx’s NLRP3 inhibitors best in class? Lilly offers $1.2B - BioWorld MedTech
FDA Limits Oversight of Fitness Wearables as Eli Lilly Acquires Ventyx Biosciences in $1 Billion Deal - geneonline.com
2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition - Law360
Lilly Snags Ventyx For $1.2 Billion; Who Else Benefits? - Investor's Business Daily
Eli Lilly Scoops Up Ventyx Biosciences in $1.2 Billion Acquisition - NAVLIN DAILY
Lilly’s Ventyx Buyout Will Swell Interest In NLRP3 inhibitors - Citeline News & Insights
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX) - MarketScreener
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition - MedCity News
Lilly buys Ventyx in $1.2bn deal to tackle chronic inflammation - BioXconomy
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences - PharmExec.com
Eli Lilly (LLY) Buys Ventyx Biosciences in $1.2 Billion Deal - TipRanks
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal - Asianet Newsable
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1? - Yahoo Finance
Lilly to acquire Ventyx Biosciences stock for $14 per share - Investing.com
Lilly Agrees to Acquire Ventyx Biosciences - Contract Pharma
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next - TechStock²
Lilly acquires inflammatory firm Ventyx Biosciences for $1.2bn deal - European Pharmaceutical Review
Eli Lilly stock to acquire Ventyx for $1.2 billion, Cantor Fitzgerald maintains Overweight rating - Investing.com
Lilly announces acquisition of Ventyx Biosciences for around $1.2bn - PMLiVE
VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders - Bluefield Daily Telegraph
Ventyx Biosciences (VTYX) Stock Rally Cools as $1.2B Eli Lilly Takeover Triggers Target Cuts - TipRanks
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion to Expand Inflammatory Disease Portfolio - geneonline.com
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact - BioSpace
Lilly buys inflammation biotech Ventyx for $1.2B in wake of Parkinson's, CV readouts - Fierce Biotech
Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion - GuruFocus
Lilly confirms bid to acquire Ventyx Biosciences - The Pharma Letter
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn - Pharmaceutical Technology
Ventyx Biosciences jumps on report Eli Lilly nears more than $1B deal - MSN
Ventyx Biosciences downgraded to Hold from Buy at Canaccord - TipRanks
Ventyx Biosciences downgraded to Neutral from Buy at UBS - TipRanks
Lilly to acquire Ventyx Biosciences stock for $1.2 billion, Canaccord cuts rating - Investing.com Canada
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition - Investing.com Canada
Eli Lilly to acquire Ventyx Biosciences stock for $1.2 billion as Clear Street downgrades - Investing.com
Lilly Commits $1.2B to Transform Oral Therapy Landscape with Ventyx Acquisition - geneonline.com
Lilly Inks $1.2bn Deal For Ventyx In Broader Pipeline Expansion - Citeline News & Insights
Significant price jump for US biotech company - medwatch.com
Eli Lilly (LLY) to Acquire Ventyx Biosciences in $1.2 Billion De - GuruFocus
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - The Malaysian Reserve
Ventyx downgraded to Market Perform from Outperform at LifeSci Capital - TipRanks
Eli Lilly to Acquire Drug Developer Ventyx for $1.2 Billion, Expanding in Autoimmune Field - Bitget
Lilly to buy Ventyx Biosciences for $1.2 billion - Indian Pharma Post
Shareholder Alert: The Ademi Firm investigates whether Ventyx Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders - Morningstar
Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion, Expanding Inflammation Portfolio - NAI500
Confirming rumours, Lilly to buy Ventyx in $1.2B deal - FirstWord
Eli Lilly confirms plan to buy Ventyx Biosciences in $1.2 billion deal - MSN
Ventyx Biosciences Inc (VTYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):